Elan and Biogen hoping to relaunch MS drug
Elan and Biogen Idec are hoping to relaunch their drug Tysabri to the market as a treatment for multiple sclerosis.
They have said they expect to submit additional safety information to US regulators in the next few weeks.
The Business Hub
Newsletter
News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.





